169 related articles for article (PubMed ID: 38154193)
1. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract][Full Text] [Related]
2. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
3. The International Consensus Classification of myelodysplastic syndromes and related entities.
Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
[TBL] [Abstract][Full Text] [Related]
4. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
[TBL] [Abstract][Full Text] [Related]
6. Implications of the 5
Lee C; Kim HN; Kwon JA; Yoon SY; Jeon MJ; Yu ES; Kim DS; Choi CW; Yoon J
Ann Lab Med; 2023 Sep; 43(5):503-507. PubMed ID: 37080752
[TBL] [Abstract][Full Text] [Related]
7. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
8. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
9. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.
Bruehl FK; Osman MM; Chen D; Dalland JC
J Hematop; 2023 Jun; 16(2):65-71. PubMed ID: 38175439
[TBL] [Abstract][Full Text] [Related]
10. Impact of the International Consensus Classification of myelodysplastic syndromes.
Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
[TBL] [Abstract][Full Text] [Related]
11. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
[TBL] [Abstract][Full Text] [Related]
13. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
Hoff FW; Madanat YF
Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
15. Risk stratifying MDS in the time of precision medicine.
Cazzola M
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
[TBL] [Abstract][Full Text] [Related]
16. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
17. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
18. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
19. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
Aguirre LE; Al Ali N; Sallman DA; Ball S; Jain AG; Chan O; Tinsley-Vance SM; Kuykendall A; Sweet K; Lancet JE; Padron E; Komrokji RS
Leukemia; 2023 Jul; 37(7):1530-1539. PubMed ID: 37147425
[TBL] [Abstract][Full Text] [Related]
20. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]